Issue 6/2015

Hypoglycemia associated with non-islet cell tumors (841 — 845)

D. KANTAROVA, I. SAGOVA, M. STANCIK, J. SADLONOVA

DOI: 10.4149/neo_2015_102

Long Noncoding RNA: its partners and their roles in cancer (846 — 854)

Z. LIN, Y. HU, S. LAI, M. XUE, J. LIN, Y. QIAN, W. ZHUO, S. CHEN, J. SI, L. WANG

DOI: 10.4149/neo_2015_103

MicroRNA-219-5p functions as a tumor suppressor partially by targeting platelet-derived growth factor receptor alpha in colorectal cancer (855 — 863)

G. B. XIONG, G. N. ZHANG, Y. XIAO, B. Z. NIU, H. Z. QIU, B. WU, G. L. LIN, L. YOU, H. SHU

DOI: 10.4149/neo_2015_104

Increased expression of amyloid precursor protein promotes proliferation and migration of AML1/ETO-positive leukemia cells and be inhibited by panobinostat (864 — 871)

C. L. WANG, B. J. DING, L. JIANG, C. X. YIN, Q. X. ZHONG, G. P. YU, X. D. LI, F. Y. MENG

DOI: 10.4149/neo_2015_105

Silencing ECHS1 attenuates the proliferation and induces the autophagy of hepatocellular carcinoma via impairing cell metabolism and activating AMPK (872 — 880)

W. J. XU, L. G. CHEN, X. CHEN, Y. S. LIU, T. H. ZHENG, J. J. SONG, W. XU, P. LI, M. Q. ZHANG, C. X. XIAO, B. GULENG, J. L. REN

DOI: 10.4149/neo_2015_106

Suppression of peripheral myelin protein 22 (PMP22) expression by miR29 inhibits the progression of lung cancer (881 — 886)

H. QU, M. ZHU, Y. TAO, Y. ZHAO

DOI: 10.4149/neo_2015_107

Suppression of PinX1 resulted in telomere dysfunction and enhanced radiosensitivity in osteosarcoma cell lines (887 — 893)

J. P. LI, S. W. ZHU, Y. H. CHEN, X. L. WANG, X. GAO

DOI: 10.4149/neo_2015_108

Synergism between arsenic trioxide and cyclopamine in the inhibition of PC3 cell survival via the Hedgehog signaling pathway (894 — 904)

Y. J. XIONG, Y. J. GUO, Y. R. GAO, S. LI, Z. H. DAI, X. Q. DONG, Y. F. XU, C. Q. LIU, Z. Y. LIU

DOI: 10.4149/neo_2015_109

CpG Oligodeoxynucleotide1826 combined with radioresistant cancer cell vaccine confers significant antitumor effects (905 — 914)

X. B. ZHUANG, N. XING, Q. ZHANG, S. J. YUAN, W. CHEN, T. K. QIAO

DOI: 10.4149/neo_2015_110

Trefoil factor 3 is required for differentiation of thyroid follicular cells and acts as a context-dependent tumor suppressor (914 — 924)

A. ABOLS, K. DUCENA, D. ANDREJEVA, L. SADOVSKA, E. ZANDBERGA, J. VILMANIS, Z. NARBUTS, J. TARS, J. EGLITIS, V. PIRAGS, A. LINE

DOI: 10.4149/neo_2015_111

FBXL10 contributes to the progression of nasopharyngeal carcinoma via involving in PI3K/mTOR pathway (925 — 931)

Y. REN, L. WU, X. LI, W. LI, Y. YANG, M. ZHANG

DOI: 10.4149/neo_2015_112

Decreased expression of H3K27me3 in human ovarian carcinomas correlates with more aggressive tumor behavior and poor patient survival (932 — 937)

W. P. HE, Q. LI, J. ZHOU, Z. S. H. YOU, H. F. KUNG, X. Y. GUAN, D. XIE, G. F. YANG

DOI: 10.4149/neo_2015_113

Inflammatory environment created by fibroblast aggregates induces growth arrest and phenotypic shift of human myeloma cells (938 — 948)

K. SZABOVA, I. BIZIKOVA, M. MISTRIK, J. BIZIK

DOI: 10.4149/neo_2015_114

microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia (949 — 958)

D. JURKOVICOVA, R. LUKACKOVA, M. MAGYERKOVA, L. KULCSAR, M. KRIVJANSKA, V. KRIVJANSKY, M. CHOVANEC

DOI: 10.4149/neo_2015_115

Time-course pattern of blood 25-hydroxycholecalciferol is a significant predictor of survival outcome in metastatic colorectal cancer: a clinical practice-based study (958 — 965)

R. OBERMANNOVA, L. DUSEK, K. GREPLOVA, J. JARKOVSKY, J. STERBA, R. VYZULA, R. DEMLOVA, L. ZDRAZILOVA-DUBSKA, D. VALIK

DOI: 10.4149/neo_2015_116

Identification of lung cancer oncogenes based on the mRNA expression and single nucleotide polymorphism profile data (966 — 973)

Y. WANG, Q. MEI, Y. Q. AI, R. Q. LI, L. CHANG, Y. F. LI, Y. X. XIA, W. H. LI, Y. CHEN

DOI: 10.4149/neo_2015_117

β-blockers in the treatment of periocular infantile capillary haemangioma (974 — 979)

M. PORUBANOVA, A. SHARASHIDZE, J. HORNOVA, A. GERINEC

DOI: 10.4149/neo_2015_118

High cytoplasmic expression of SALL4 predicts a malignant phenotype and poor prognosis of breast invasive ductal carcinoma (980 — 988)

X. YUE, L. XIAO, Y. YANG, W. LIU, K. ZHANG, G. SHI, H. ZHOU, J. GENG, X. NING, J. WU, Q. ZHANG

DOI: 10.4149/neo_2015_119

Enhanced International Prognostic Index (NCCN-IPI), Charlson Comorbidity Index and absolute lymphocyte count as predictors for survival of elderly patients with diffuse large B cell lymphoma treated by immunochemotherapy (988 — 995)

J. JELICIC, M. TODOROVIC BALINT, D. ANTIC, A. SRETENOVIC, B. BALINT, M. PERUNICIC JOVANOVIC, B. ANDJELIC, V. VUKOVIC, V. DJURASINOVIC, J. BILA, M. PAVLOVIC, M. SMILJANIC, B. MIHALJEVIC

DOI: 10.4149/neo_2015_120

Clinical and biological significance of erlotinib therapy after pemetrexed in non-small cell lung cancer with wild-type EGFR (996 — 1004)

N. KOYAMA, M. SUZUKI

DOI: 10.4149/neo_2015_121